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Abstract
AIM: The aim of this study was to compare the transcranial and the endoscopic transsphenoidal approaches for 
patients with recurrent giant pituitary adenomas as regards the extent of tumor resection and the clinical outcome.
METHODS: The study included 21 patients with recurrent giant pituitary adenomas divided into two groups; Group 
A included nine patients operated on by transcranial approaches and Group B included 12 patients operated on by 
the endoscopic transsphenoidal approach. Both groups were compared as regards the extent of tumor resection and 
the post-operative clinical outcome, particularly the visual and endocrinological outcomes, in addition to morbidity 
and mortality.
RESULTS: There was a higher incidence of total and near-total resection in Group B (41.7%) and a higher incidence 
of subtotal resection in Group A (55.6%). The incidence of visual improvement was higher in Group B (55.6%) than 
in Group A (28.6%). Post-operative biochemical remission was achieved in 100% of Group B patients and in 50% of 
Group A patients with functioning adenomas. The incidence of post-operative complications was higher in Group A 
(77.8%) than in Group B (50%).
CONCLUSION: The endoscopic transsphenoidal approach for recurrent giant pituitary adenomas is associated with 
a higher extent of tumor resection, better rates of visual improvement and endocrinological remission, and lower 
incidence of complications. The transcranial approach should be reserved for some adenomas with marked lateral 
or anterior extensions, fibrous tumors, and after the failure of the endoscopic transsphenoidal approach.
Introduction
Giant pituitary adenomas are 
adenomas exceeding 3–4 cm in their largest 
diameter [1], [2], [3], [4], [5]. They represent around 
5–15% of all pituitary adenomas [2], [4]. Due to 
their large size, giant adenomas usually present 
with manifestations due to mass effect, particularly 
visual affection, with or without manifestations due to 
hormonal disturbances. Other presentations include 
headache, pituitary apoplexy, and hydrocephalus 
(HCP) [6], [7], [8], [9]. Recurrent giant adenomas are 
usually nonfunctioning adenomas or prolactin-secreting 
adenomas, and less commonly to be growth hormone 
(GH)-secreting or adrenocorticotrophic hormone 
(ACTH)-secreting adenomas [4], [8], [9], [10].
Some patients with recurrent giant adenomas 
may benefit from medical treatment; however, the 
majority of the patients will need reoperation and/or 
radiation [5], [7], [11]. Whenever possible, aggressive 
surgical resection is warranted to avoid the need for 
post-operative radiation if possible or to improve the 
response and decrease the hazards of radiation if 
needed by decreasing the volume of post-operative 
residual [12]. Unfortunately, radical resection of these 
challenging cases is difficult to be achieved in many 
cases, thus multimodal treatment with surgery, radiation 
and/or medical treatment might be needed in patients 
with residual tumors for better tumor control and lower 
recurrence rate [5], [6], [7], [9], [11].
The choice of surgical approach depends on 
several factors, including the tumor’s extensions and 
consistency, the approach used in the initial surgery, and 
the surgeon’s experience and preference [7], [8], [13], [14]. 
Endoscopic transsphenoidal approaches, transcranial 
approaches, and combinations of both, whether 
simultaneously or staged, have been reported for the 
management of these challenging cases with variable 
outcomes. However, these reports were not focusing 
on recurrent giant adenomas in particular. Some of 
these articles were addressing recurrent adenomas 
irrespective of the size [15], [16], while others were 
addressing the different surgical approaches for giant 
adenomas whether fresh or recurrent [8], [9], [17].
The objective of this study was to compare 
the transcranial and the endoscopic transsphenoidal 
approaches in a group of patients with recurrent giant 
pituitary adenomas regarding the extent of tumor 
resection and the clinical outcome, particularly the 
visual and endocrinological outcomes.
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Patients and Methods
This study included 21 patients with recurrent 
giant pituitary adenomas who were operated on in 
Cairo University Hospitals in the period between 
March 2017 and March 2019 by both transcranial and 
transsphenoidal approaches. Giant adenomas were 
considered as adenomas >3 cm in the largest tumor 
diameter, while recurrence was considered as the 
reappearance of a totally resected tumor or regrowth of 
a residual tumor. All patients were indicated for surgical 
resection due to progressive neurological deterioration, 
manifestations of hormonal disturbance, and/or other 
clinical presentations, including headache. Recurrent 
adenomas <3 cm in diameter, giant nonrecurrent 
adenomas, recurrent prolactinomas responding to 
medical treatment, and patients unfit or unwilling for 
surgical intervention were excluded from the study.
All patients were subjected to thorough history 
taking and detailed clinical examination with special 
emphasis on assessment of visual acuity, ocular 
motility, visual field assessment by confrontation 
and fundus examination in addition to examination 
for features of acromegaly or gigantism, features of 
Cushing syndrome, assessment of secondary sexual 
characters, and examination for galactorrhea in females. 
Investigations included automated perimetry for visual 
field assessment, the hormonal profile including serum 
prolactin with serial dilution to exclude hook effect, GH, 
ACTH, morning and evening cortisol, thyroid-stimulating 
hormone (TSH), triiodothyronine (T3), thyroxin (T4), 
follicle-stimulating hormone, luteinizing hormone, and 
testosterone levels in addition to routine pre-operative 
laboratory investigations. Magnetic resonance imaging 
(MRI) sella with contrast was performed for all patients 
while computed tomography (CT) paranasal sinuses 
was performed for patients planned for transsphenoidal 
approach.
Patients were divided into two groups according 
to the surgical approach performed; Group A included 
nine patients who were operated on by the transcranial 
approaches and Group B included 12 patients who 
were operated on by the endoscopic transsphenoidal 
approach. The choice of the approach was based on 
multiple factors, including tumor’s configuration and 
extensions, especially lateral and anterior extensions, 
the tumor’s suspected consistency, the previously 
used surgical approach, and the surgeon’s experience 
and preferences. The tumor’s extensions into various 
compartments were demonstrated on MRI. The firm 
consistency of the tumor could be predicted using 
different MRI sequences as T2-weighted images 
and diffusion-weighted images. Some surgeons 
preferred a transcranial approach following an initial 
transsphenoidal approach to avoid going through 
adhesions and distorted anatomical landmarks, while 
others preferred a transcranial approach when they 
suspected preoperatively that the tumor extensions 
and consistency would be difficult to reach and manage 
through the transsphenoidal approach. Surgeons with 
more familiarity with the transsphenoidal approaches 
have preferred to use it, especially when the lesion 
had no or minimal parasellar extension. Surgeons’ 
preference was one of the important factors affecting 
the choice of the approach.
Post-operative evaluation stressed on 
assessment of conscious level, visual acuity and 
field, cranial nerves, motor power, hypothalamic 
manifestations, or other neurological deficits. Morbidity 
in the form of cerebrospinal fluid (CSF) leak, infection, 
visual and neurological deficits, diabetes insipidus 
(DI), and other endocrinopathies were recorded. The 
cause and timing of mortality were also documented. 
Hormonal assay was obtained in the early post-
operative period and endocrinological remission was 
assessed in patients with functioning adenomas. 
Patients with endocrinopathies were referred to an 
endocrinologist. An early post-operative CT scan or 
MRI was performed before discharge. MRI sella with 
contrast was performed 3 months after surgery when 
immediate post-operative MRI was not performed to 
determine the extent of resection.
Patients were followed up in the outpatient 
clinic for 1 month and 3 months after surgery. The 
outcome was assessed as regards the extent of 
resection (primary outcome), the clinical outcome, 
especially the visual outcome, the endocrinological 
remission, and the incidence of morbidity and 
mortality (secondary outcomes). The extent of 
tumor resection was categorized based on the 
post-operative MRI into total or near-total resection 
(>90%), subtotal resection (70–90%), and partial 
resection (<70%). The endocrinological outcome in 
patients with functioning adenomas was categorized 
as cured if the serum hormone level was normalized, 
improved if there was >50% reduction of the pre-
operative serum hormone level, and unchanged if 
reduction was <50%.
Statistical methods
Data of patients were coded and entered 
using the Statistical Package for the Social Sciences 
version 25. Data were summarized using mean, 
standard deviation, median, minimum, and maximum 
for quantitative data and using frequency (count) and 
relative frequency (percentage) for categorical data. 
Comparisons between quantitative variables were 
done using the nonparametric Mann-Whitney test. 
For comparing categorical data, Chi-square test was 
performed. Exact test was used instead when the 
expected frequency was <5. P < 0.05 was considered 
as statistically significant.
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All patients in Group A were operated on by the 
pterional approach and its modifications; six patients 
from the right side and three patients from the left side. 
Three of these patients have been previously operated 
on by a transcranial approach, right pterional approach 
in one patient, left pterional approach in one patient, and 
right subfrontal approach in the third patient. All three 
patients were approached from the same side of the 
previous approach with the craniotomy flap enlarged 
in the patient with previous subfrontal approach into a 
frontotemporal craniotomy. All patients in Group B were 
operated on by the conventional endoscopic endonasal 
transsphenoidal approach without the use of navigation; 
nine of them have been operated on by the endoscopic 
transsphenoidal approach in the primary surgery.
The extent of resection in both groups is shown 
in Table 2. The limitations to radical resection in our series 
included cavernous sinus invasion, significant anterior or 
middle fossa extensions, marked suprasellar extension 
into the third ventricle, and firm consistency. Factors 
hindering gross total resection included cavernous 
sinus invasion in six cases, marked suprasellar, middle 
fossa or anterior fossa extension in seven cases, and 
firm consistency in five cases, with more than one factor 
being present some cases. These factors especially 
the marked extension into the anterior or the middle 
cranial fossa and the firm consistency made the extent 
of resection lower in the cases operated on using the 
transcranial approach (Group A).
Results
This prospective study included 21 patients 
with recurrent giant pituitary adenomas who were 
divided into two groups according to the performed 
surgical approach. Group A included nine patients who 
were operated on by the transcranial approaches and 
Group B included 12 patients who were operated on 
by the endoscopic transsphenoidal approach. Patients’ 
demographics, data of previous treatments, and tumors’ 
types are summarized in Table 1.
Table 1: Patients’ demographics, data of previous treatments, 
and tumors’ types
Group A Group B p value
Gender
Male 5 (55.6%) 8 (66.7%) 0.673
Female 4 (44.4%) 4 (33.3%)
Age (years)
Minimum 23 24 0.651
Maximum 64 65
Mean 47.11 43.75
Number of previous surgeries
1 7 9 0.472
2 2 1
3 - 2
Interval since last surgery (years)
Minimum 1 1 0.651
Maximum 7 6
Mean 3.89 3.5
Previous route
Transsphenoidal 6 (66.7%) 9 (75.0%)
Transcranial 3 (33.3%) 3 (25.0%)
Previous radiation
Yes 1 -
No 8 12
Previous medical treatment
Yes 2 1
No 7 11
Type of adenoma
Non-functioning 7 (77.8%) 9 (75.0%) 0.472
Prolactinoma 2 (22.2%) 1 (8.3%)
GH-secreting 0 2 (16.7%)
The clinical presentations of the patients in both 
groups are shown in Figure 1. 
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Figure 1: Chart showing clinical presentations in both groups
One of the important factors that influenced the choice 
of the operative approach was the extensions of the 
tumor into the various nearby compartments. Figure 2 
shows the various tumors’ extensions in both groups. 
A significant extension of the adenoma into the 
parasellar region, particularly lateral or superolateral 
to the cavernous sinus into the middle fossa, favored 
the choice of the transcranial approach. Similarly, 
significant tumor extension into the anterior cranial 
fossa favored the choice of the transcranial approach. 
On the other hand, cavernous sinus invasion did not 
favor an approach over the other.
Table 2: Extent of tumor resection in both groups
Extent of resection Group A Group B Total p-value
n % n % n %
Total and near total 1 11.1 5 41.7 6 28.6 0.185
Subtotal 5 55.6 3 25 8 38.1
Partial 3 33.3 4 33.3 7 33.3
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Figure 2: Chart showing tumor extensions in both groups
As regards the visual outcome, two of the seven 
surviving patients (28.6%) with pre-operative visual 
affection in Group A showed improvement while five 
patients (71.4%) remained stationary, and there was no 
visual deterioration in any patient. Five of the nine (55.6%) 
patients with pre-operative visual affection in Group 
B showed improvement, while four patients (44.4%) 
remained stationary, and there was no visual deterioration 
in any patient. The incidence of visual improvement in 
the whole study group was 43.8%. Headache was the 
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presenting symptom in seven patients in Group A and 
in eight patients in Group B. All of the patients showed 
improvement in their headaches postoperatively.
Regarding functioning adenomas, normalization 
of the hormonal level was achieved in 100% of the patients 
with GH-secreting adenomas and in 66.7% of the patients 
with prolactin-secreting adenomas. The two patients 
with hormonal hyper function in Group A (100%) showed 
normalization in one patient and improvement (>50% 
reduction) in the other. Regarding the three patients 
with hormonal hyper function in Group B, biochemical 
remission was achieved in all three patients (100%).
Post-operative complications included new 
hormonal deficiency, DI, post-operative intracerebral 
hematoma (ICH), CSF rhinorrhea, HCP, fits, and 
development of 3rd nerve palsy (Figure 3). The incidence 
of complications in the whole study group was 61.9%; 
being higher with the transcranial approach (77.8%) 
than with the endoscopic transsphenoidal approach 
(50%). However, the difference was not statistically 
significant (p = 0.367). There was a single mortality 
in this study which occurred in a patient in Group A. 
The patient did not recover well after surgery due to 
hypothalamic affection. CT brain showed a small 
frontal ICH that could not explain the poor conscious 
level and was managed conservatively. The patient 
further deteriorated and died 10 days later from chest 
infection and sepsis. Regarding the two patients with 
post-operative CSF rhinorrhea, one was managed 
conservatively and the leak stopped after 5 days, while 
the other patient needed endoscopic repair 7 days 
later with a stoppage of the leak. One patient with ICH 
was managed conservatively as previously mentioned, 
while the other patient was managed by surgical 
evacuation of the hematoma together with insertion of a 
ventriculoperitoneal shunt due to the presence of HCP, 
and the patient recovered well after surgery.
whether fresh or recurrent [8], [9], [17]. However, 
there were no articles focusing on the management of 
recurrent giant adenomas in particular. In addition, in 
most of the above-mentioned articles the patients with 
“recurrent giant” tumors were not grouped together 
as a separate subset or group of patients, but were 
rather dispersed among the rest of the patients. Our 
study included 21 patients with recurrent giant pituitary 
adenomas operated on by transcranial (Group A) or 
endoscopic transsphenoidal (Group B) approaches, thus 
representing a unique series focusing on recurrent giant 
adenomas in particular. The patients’ demographics, 
data of previous treatments, tumor types, and clinical 
presentation were comparable between both groups 
with no statistically significant difference.
The optimal surgical approach for giant 
adenomas is still debatable. Tumor’s extensions 
represented an important factor in the choice of the 
surgical approach. Suprasellar extension was present 
in all our cases and it did not affect the choice of the 
approach unless a constriction was found at the 
diaphragm. Several authors considered significant 
suprasellar extension especially when dumbbell-shaped 
as an indication for transcranial surgery [11], [13], [14]. 
On the other hand, several authors did not consider 
this as an indication for transcranial surgery and have 
reported favorable outcomes with the endoscopic 
transsphenoidal approach (including expanded 
approaches) which provides a direct access along the 
tumor axis [8], [16], [18]. Cavernous sinus invasion 
was found in 28.6% of our cases, and its presence 
did not influence the choice of the approach in our 
study as well as in many other series as it presents 
a common limitation for radical tumor resection 
irrespective of the approach [8], [17], [19]. Four cases 
(19%) had marked extensions into the middle and 
anterior cranial fossa and all were operated on by 
transcranial approaches. Similarly, several authors 
considered significant tumor extension into the middle 
or anterior fossa among the indications for transcranial 
approaches [11], [13], [14], [20]. On the other hand, de 
Divitiis et al. mentioned that adenomas with significant 
anterior or lateral extensions could be approached by 
expanded endoscopic approaches [21]. Koutourousiou 
et al. reported that tumors extending into the lateral 
cavernous sinus and the middle fossa could not be 
totally resected unless a transcranial approach was 
performed; however, they preferred a conservative 
approach and recommended managing these lesions 
with transsphenoidal approaches leaving a small 
residual [8].
Tumor consistency was another important factor 
in the choice of the surgical approach. De Divitiis et al. 
mentioned that fibrous adenomas could be approached 
by expanded endoscopic approaches [21]. Moreover, 
Jane et al. mentioned that firm tumor consistency did 
not have a consistently adverse effect or increase the 
complications of repeat transsphenoidal surgery [7]. 
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Figure 3: Chart showing different complications in both groups
Discussion
Many clinical series have addressed recurrent 
pituitary adenomas irrespective of the size [15], [16], 
while others have addressed giant pituitary adenomas 
 Ismail et al. Management of Recurrent Giant Pituitary Adenomas
Open Access Maced J Med Sci. 2020 Apr 08; 8(B):273-280. 277
Other authors argued that with the transsphenoidal 
approach it might be difficult to manage firm and 
fibrous adenomas especially when giant and recurrent 
with adhesions, as this could increase the morbidity 
from damage to surrounding structures, making a 
transcranial or a combined approach preferred in such 
adenomas [7], [13], [14], [20], [22], [23]. Thus, it was 
important to predict tumor consistency before surgery to 
help in the choice of the best approach. Firm consistency 
could be anticipated from different MRI sequences, 
history of the previous radiotherapy, and history of 
previous medical treatment [7], [20], [24], [25], [26].
Another additional important factor affecting 
the choice of the approach in recurrent cases was the 
previous surgical approach. Failure to achieve the goal 
of surgery through the transsphenoidal approach was 
considered as an indication for transcranial approaches 
by some authors [13], [22], [27], whereas other authors 
recommended repeat transsphenoidal surgery [18], [28]. 
In cases with a previous transsphenoidal approach, 
there might be anatomical landmark distortion adding 
more difficulty to the repeated transsphenoidal surgery; 
however, this can be overridden using frameless 
stereotaxy or intraoperative MRI [18], [29], [30]. In 
cases with previous transcranial approach, dense 
arachnoid adhesions and partial or complete absence 
of diaphragm may add to the risks and complications of 
transsphenoidal approach, including higher incidence 
of post-operative CSF leak [18], [31]. Similarly, if 
transcranial approach was performed following a 
transsphenoidal approach with inadequate sphenoid 
sinus obliteration, the probability of CSF rhinorrhea 
is high [27]. Several authors advocated the use of 
the endoscopic transsphenoidal approaches for all 
recurrent adenomas including giant tumors, irrespective 
of the primary approach [8], [15], [18]. Cavallo et al. 
reported that the endoscopic transsphenoidal approach 
following transcranial surgery allow using a naïve route 
in addition to obtaining an inverse view of the surgical 
field with accessibility to previously inaccessible tumor 
parts. However, their extent of resection was much 
lower in patients previously operated on by transcranial 
approaches [18]. Nishioka et al. reported the use 
of combined approaches for these recurrent giant 
cases irrespective of the previous approaches. The 
transcranial part of the combined approach was thought 
to be more helpful in management of the parasellar and 
high suprasellar parts [23].
Extent of tumor resection represents an 
important factor in the outcome assessment. More 
radical extent of resection leads to longer recurrence-free 
(progression-free) interval and better outcome. Several 
authors categorized the extent of resection of pituitary 
adenomas in various ways using different cutoffs for each 
category, thus making a uniform definition for the extent 
of resection non-applicable, and making comparisons 
with other authors about the achieved extent of resection 
difficult [8], [9], [12], [15, [16], [17], [18]. We achieved 
total or near-total resection in 28.6%, subtotal 
resection in 38.1%, and partial resection in 33.3% of 
all patients. The limitations to radical resection in our 
series included cavernous sinus extensions, significant 
anterior or middle fossa extensions, marked suprasellar 
extension into the third ventricle, and firm consistency. 
Similar limitations for radical resection were reported 
in several clinical series [8], [9], [17]. In cases with 
parasellar extension, our goal was to decompress the 
optic apparatus and reduce the tumor burden. The 
residual tumor was managed by radiosurgery, medical 
treatment, or followed up. Several studies encouraged 
safe excision of adenomas while leaving the cavernous 
portion for radiosurgery as long as an adequate 
distance (>5 mm) exists between the residual tumor 
and the optic apparatus [8], [11], [13], [32].
Nishioka et al. achieved total resection in 
15.4%, subtotal resection in 76.9%, and partial resection 
in 7.7% of their 13 patients with recurrent adenomas 
(>3 cm) operated on by combined approach [23]. Using 
various surgical approaches, Han et al. achieved >90% 
tumor resection in 55.6% of their patients with recurrent 
giant adenomas [9]. Koutourousiou et al. reported 
gross total resection, near-total resection, and partial 
resection in 6.2%, 18.8%, and 75% of their patients with 
recurrent giant adenomas, respectively [8]. Nishioka 
et al. achieved total resection, subtotal resection with 
residue in the cavernous sinus, and subtotal or partial 
resection with residue outside the cavernous sinus in 
13.5%, 54.1%, and 32.4% of their recurrent patients, 
respectively [17]. The significantly reduced extent of 
resection reported by these authors in recurrent cases 
as compared to their extent of resection in fresh cases 
emphasizes the difficulty to achieve adequate extent 
of resection in these recurrent cases. Furthermore, 
the generally less favorable outcome following surgical 
resection of recurrent giant adenomas did not differ 
significantly among authors using different surgical 
approaches. Moreover, even the combined approaches 
did not achieve significantly better resection in 
management of these challenging tumors mostly due 
to multi-compartmental extensions particularly into the 
cavernous sinus.
Comparing both groups, the percentage of total 
and near-total resection was clearly higher in Group B; 
however, the difference was not statistically significant. 
The incidence of suprasellar extension and cavernous 
sinus invasion was comparable in both groups; however, 
marked tumor extensions into the middle or the anterior 
fossa were only found in Group A and fibrous tumors 
were more common in Group A, which might explain the 
difference between both groups regarding the extent of 
resection. Koutourousiou et al. analyzed their extent of 
resection according to tumor extensions and reported 
that tumor extensions into the anterior fossa, posterior 
fossa, or the third ventricle were associated with a lower 
incidence of gross total resection in comparison to the 
whole study group, with the lowest incidence being with 
tumors having anterior cranial fossa extensions [8]. 
In their systematic review, Komotar et al. found that 
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gross total resection was achieved in 9.6% and 
47.2% of the patients operated on by transcranial and 
endoscopic transsphenoidal approaches, respectively. 
Their findings are comparable to our results in both the 
transcranial and the transsphenoidal groups; however, 
not all of their included giant cases were recurrent [5]. 
On the other hand, Han et al. achieved >90% resection 
of giant adenomas including recurrent cases in 75% 
(all three patients had gross total resection) and 76.7% 
(gross total resection in only one-third of them) of the 
cases following the transcranial and the transsphenoidal 
approaches, respectively [9].
Regarding the whole study group, visual 
improvement was achieved in 43.8% of the patients 
with pre-operative visual affection, with no visual 
deterioration in any patient. The rate of visual 
improvement in patients with giant adenomas 
(including some recurrent cases) having pre-operative 
visual affection in several series ranged between 53% 
and 80%, while the incidence of visual deterioration 
ranged between 0% and 4.8% [4], [8], [9], [23]. In the 
above-mentioned series, there was no data regarding 
the outcome in recurrent giant cases in particular. The 
lower incidence of visual improvement in our series 
in comparison with other series might be due to their 
inclusion of both recurrent and fresh giant adenomas 
while our series included only recurrent giant cases. 
Nishioka et al. reported visual improvement in 79.1% 
and visual deterioration in 3.6% of their patients, 
however, when they analyzed the subgroup of patients 
with stationary vision or visual deterioration they found 
that this occurred in 14.1% with fresh adenomas and 
in 37.5% with recurrent adenomas which goes with 
our findings regarding the lower incidence of visual 
improvement in recurrent giant cases [17].
Visual improvement was achieved in 28.6% 
in Group A and in 55.6% in Group B. In Han et al. 
series, visual improvement was achieved in 50% and 
81.4% of the patients operated on by transcranial and 
transsphenoidal approaches, respectively, which goes 
with our findings that visual improvement was higher 
in the transsphenoidal group than with the transcranial 
group [9]. Similarly, Komotar et al. in their systematic 
review reported much better results with the endoscopic 
transsphenoidal approach (91.1% improvement with no 
deterioration) as compared to the transcranial approaches 
(40% improvement and 22.9% deterioration). This might 
be due to the selection of transcranial approaches for the 
more complicated cases [5].
Regarding functioning adenomas, normalization 
of the hormonal level was achieved in 100% of the 
patients with GH-secreting adenomas and in 66.7% of the 
patients with prolactin-secreting adenomas. Subgroup 
analysis showed a 50% remission rate in the transcranial 
group and 100% remission rate in the transsphenoidal 
group. Han et al. achieved endocrinological remission 
in three of their five patients (60%) with GH-secreting 
adenomas operated on by the transsphenoidal 
approach and in the single patient (100%) operated on 
by combined approach, while it was not achieved in any 
of the two patients with prolactinomas operated on by 
the transsphenoidal approach [9]. In Wang et al. series 
of 36 giant adenomas, improvement (normalization or 
reduction of hormone level by >25%) occurred in 71.4% 
of prolactinomas and in all three cases of GH-secreting 
and TSH-secreting adenomas; however, there were no 
recurrent cases in their series [33].
Surgery in recurrent cases has a higher risk of 
complications and the giant size adds more to the risk. 
Complications rate in our series (61.9%) was higher 
than that reported in several clinical series which might 
be explained by the inclusion criteria in each study, 
with our study including only recurrent giant adenomas 
in contrast to the other studies. Furthermore, some 
clinical series did not include the newly developed post-
operative pituitary insufficiency in their complications. 
Nishioka et al. reported complications apart from 
pituitary dysfunction in 46.2% of their patients with 
recurrent adenomas >3 cm and they stated that these 
complications were transient [23]. Tajudeen et al. 
reported minor complications in 22% of their patients; 
however, only six of their 27 recurrent adenomas 
were giant [15]. Nishioka et al. reported permanent 
neurological deficits and permanent hypopituitarism 
and DI in only 24.3% of their patients with recurrent giant 
adenomas, however, they reported the occurrence of 
other complications, including visual deterioration, CSF 
leak, and meningitis in their patients but their incidence 
in recurrent cases was not specified [17].
The incidence of complications was higher 
with the transcranial approach (77.8%) than with the 
endoscopic transsphenoidal approach (50%) with no 
statistically significant difference. These results might 
need cautious interpretation as the transcranial approach 
was reserved for more extensive and challenging 
tumors which are more likely to have post-operative 
complications. Han et al. reported a much higher 
incidence of pituitary insufficiency, DI, and electrolyte 
imbalance following the transcranial approach and 
higher incidence of CSF leak and meningitis following the 
transsphenoidal approach [9]. Komotar et al. reported 
no complications in only 17.5% of the patients operated 
on by transcranial approaches, which is close to our 
complication rate in the transcranial group. Reported 
complications included hypopituitarism, permanent DI, 
CSF leak, and cerebral infarction. Mortality was reported 
in 10.6% of the transcranial cases which is similar to 
our results. Regarding the endoscopic transsphenoidal 
approach, much lower complication rate was reported 
(13% of the cases) and complications included DI, 
sinusitis, pulmonary embolism, and hemorrhage [5].
Study limitations
Limitations included the small number of 
cases in each group which is due to the low incidence 
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of recurrent giant adenomas, the difference between 
both groups as regards the tumors’ extensions which 
may interfere with the choice of the approach and the 
results and the non-randomization of patients to both 
groups. In addition, not all cases were operated on by 
the same surgeon which might affect the results. Future 
randomized studies with a larger number of patients 
and longer follow-up periods are recommended.
Conclusion
The endoscopic transsphenoidal approach 
is associated with a higher extent of tumor resection, 
better rates of visual improvement and endocrinological 
remission, and lower incidence of complications 
as compared to the transcranial approach in the 
management of recurrent giant pituitary adenomas. 
However, these superior results might be affected 
by the more complexity of the cases selected for 
the transcranial approach. Thus, the endoscopic 
transsphenoidal approach should be considered as 
the first choice for these challenging lesions, with the 
transcranial approach reserved for some lesions with 
marked lateral or anterior extensions, fibrous tumors, 
and after the failure of the endoscopic transsphenoidal 
approach.
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